

Special Issue

Recent Advances in Primary and Relapsed Ovarian Cancer

Message from the Guest Editor

Among gynecological cancers, ovarian cancer is the leading cause of death, and it is the fifth most frequent cause of death overall. In recent years, immunotherapy and targeted therapy have widened the spectrum of therapeutical options. Despite these options, many patients relapse over time. BRCA mutation and HRD testing are of great importance. Many treatment modalities have been added to standard therapy, but a better understanding of the genetic and molecular characterization of ovarian cancer and HGSOC is still needed. Furthermore, mechanisms of resistance to therapy, the impact of BRCA1/2 status and tumor heterogeneity must be investigated in the future. New treatment options based on a better understanding of the molecular characterization of this cancer and reasons for chemoresistance are needed. This Special Issue will highlight the broad spectrum of research in primary and relapsed ovarian cancers, and invites manuscripts of clinical trials, basic research, genetic testing, tumor cell heterogeneity, causes of chemoresistance and novel research ideas in this context.

Guest Editor

Dr. Cornelia Bachmann

Department of Women's Health Tübingen, Eberhard Karls University Tübingen, 72076 Tübingen, Germany

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/206802

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).